I found the field of Pharmacology & Pharmacy very interesting. Saw the article Discovery and Synthesis of a Pyrimidine-Based Aurora Kinase Inhibitor to Reduce Levels of MYC Oncoproteins published in 2021. Product Details of 50-84-0, Reprint Addresses Chi, YH; Chang, CP (corresponding author), Natl Hlth Res Inst, Inst Biotechnol & Pharmaceut Res, Zhunan 35053, Taiwan.; Chi, YH (corresponding author), China Med Univ, Grad Inst Biomed Sci, Taichung 40402, Taiwan.; Chang, CP (corresponding author), Chung Yuan Christian Univ, Dept Chem, Taoyuan 320314, Taiwan.. The CAS is 50-84-0. Through research, I have a further understanding and discovery of 2,4-Dichlorobenzoic acid
The A-type Aurora kinase is upregulated in many human cancers, and it stabilizes MYC-family oncoproteins, which have long been considered an undruggable target. Here, we describe the design and synthesis of a series of pyrimidine-based derivatives able to inhibit Aurora A kinase activity and reduce levels of cMYC and MYCN. Through structure-based drug design of a small molecule that induces the DFG-out conformation of Aurora A kinase, lead compound 13 was identified, which potently (IC50 < 200 nM) inhibited the proliferation of high-MYC expressing small-cell lung cancer (SCLC) cell lines. Pharmacokinetic optimization of 13 by prodrug strategies resulted in orally bioavailable 25, which demonstrated an 8-fold higher oral AUC (F = 62.3%). Pharmacodynamic studies of 25 showed it to effectively reduce cMYC protein levels, leading to >80% tumor regression of NCI-H446 SCLC xenograft tumors in mice. These results support the potential of 25 for the treatment of MYC-amplified cancers including SCLC.
Product Details of 50-84-0. About 2,4-Dichlorobenzoic acid, If you have any questions, you can contact Chi, YH; Yeh, TK; Ke, YY; Lin, WH; Tsai, CH; Wang, WP; Chen, YT; Su, YC; Wang, PC; Chen, YF; Wu, ZW; Yeh, JY; Hung, MC; Wu, MH; Wang, JY; Chen, CP; Song, JS; Shih, C; Chen, CT; Chang, CP or concate me.
Reference:
Chloride – Wikipedia,
,Chlorides – an overview | ScienceDirect Topics